Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MERCK DOWNPLAYS TAGAMET EXPERIENCE FOR PEPCID AC OTC SWITCH REVIEW

This article was originally published in The Tan Sheet

Executive Summary

MERCK DOWNPLAYS TAGAMET EXPERIENCE FOR PEPCID AC OTC SWITCH REVIEW during an April 12 meeting with securities analysts at Merck's research facilities in Rahway, N.J. Merck Research Labs President Edward Scolnick, MD, maintained that Merck has "much better data" on its H[2] antagonist Pepcid (famotidine) for the treatment of heartburn than SmithKline Beecham had for Tagamet (cimetidine). "It is a completely different world of clinical research that our group has generated," Scolnick told the analysts.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082685

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel